But the daily reality for many senior validation professionals in a large regulated organization is not just a project. It is a portfolio of several applications intertwined with complex integrations and interfaces with a massive amount of regulated data. And managing a portfolio of several GxP-validated systems simultaneously to ensure quality and compliance is a fundamentally different challenge.
What a Modern IT GxP Portfolio Actually Looks Like
In any pharmaceutical or medical device organization today, the GxP-validated system portfolio covers several distinct domains in parallel. Enterprise resource planning systems manage manufacturing, procurement, inventory management, and supply chain management. Clinical and pharmacovigilance platforms manage adverse event reporting, clinical trial data capture and regulatory submissions. Quality management systems handle corrective and preventive actions (CAPAs), deviations, and quality events. Data analytics, engineering and reporting platforms help provide insights of product quality ultimately impacting patient safety. Validation lifecycle management tools maintain the evidence records for all of the above.
Every process area has its own regulatory scope, change control mechanism, vendor or third-party update schedule and most importantly, its own risk profile. The validation professionals responsible for all of these processes and systems cannot treat each one as a standalone effort.
The extent of the effort becomes apparent so quickly in practice. This is very true as the same validation professional may be assessing the GxP impact of a vendor patch to a clinical data management system, reviewing change requests for an enterprise resource planning (ERP) configuration that touches downstream integrations, investigating root causes for a CAPA, and determining whether a new analytics dashboard needs a full-blown validation lifecycle. All of these are independent and not at all the same type of work. Each carries its own regulatory compliance risk and requires a targeted validation strategy. The mental load of comprehending each of these activities and its risk outcome requires an expert-level brain-tuning that no guidance document explicitly describes. This is not a constraint of a specific validation professional but it pertains to how organizations perceive quality and streamline the governance around all their quality systems.
At the same time, this is not a problem unique to any single organization or a business functional area. It is in fact structural. The way validation professionals are trained, the way the standard operating procedures are written, and the way the quality management system (QMS) is designed assume that the unit of work is a single system. The reality of modern regulated industries is that systems do not exist in isolation but they exist in ecosystems. Treating them as isolated systems narrows compliance thinking, which is the gap that inspectors find.
The “Validated State” Problem at Scale
ISPE GAMP® 5 (Second Edition) clearly mentions that validated systems require periodic review to confirm continued validated state. The practical question arises when one is responsible for a portfolio of several systems with different risk profiles, different change frequencies, and different regulatory requirements.
Maintaining a validated state of a single system cannot map cleanly to a portfolio where some systems receive vendor updates every two weeks and others have not been changed in two years. The risk of over-validating low-risk systems and under-validating high-risk systems is real. This is not a question of effort but this is a question of governance design itself. The GxP validation governance needs to be risk-stratified across the portfolio, not applied uniformly to each system separately.
The Change Control Cascade Nobody Talks About
One of the most complex challenges in GxP portfolio management is the cascade effect of a change. For instance, a configuration change in an ERP system that integrated with an eQMS system where the data is utilized to make quality decisions using a data analytics platform does not create one change control event. It creates three at a minimum, with downstream validation implications including risk management that must be assessed and documented for each connected system even when the change is minor.
Managing this cascade of change events requires the validation professional to hold a mental map of every integration in the portfolio and to ask which other validated systems does this touch? When this question is asked repeatedly, consistently and systematically, it makes a difference between a portfolio that stays in validated state and one that gathers quiet compliance gaps that surface during an inspection later.
Where Focus Belongs When Focus Cannot Be Applied Everywhere
One of the key and utmost important skills in this era of computer system assurance: portfolio validation governance should not be tied to documentation or procedural knowledge, rather, it is to triage, by knowing which systems in the portfolio carry the highest risk of compliance failure at any given moment and concentrating expert attention and highest validation rigor there.
Risk proportionality does not stop at the boundary of a single system, it has to extend to how a validation and quality team allocates its time, attention, and expertise across every system it is responsible for. On an honest note, that allocation decision is made every day, whether consciously made or not.
The compliance frameworks are primarily built around individual systems. However, the validation practitioners responsible for those systems work at portfolio scale in reality. Closing this gap by adopting technology, tools, innovative yet compliant governance frameworks, and how effectively we communicate the expectations about validation work is the next practical frontier for this community.
